Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits

Bilateral Secondary Angle Closure During Daratumumab Infusion: A Case Report and Review of the Literature

(2020) Rebecca G. Edwards et al.   JOURNAL OF GLAUCOMA

Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus

(2020) Lennard Ostendorf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

(2019) Thierry Facon et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy


(2018) Nicola Lepori et al.   CLINICAL NEPHROLOGY

Bilateral Angle Closure Following the Infusion of a Monoclonal Antibody to Treat Relapsing Multiple Myeloma

(2018) Andrew Lee et al.   JOURNAL OF GLAUCOMA

Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft

(2018) Samar M. Said et al.   KIDNEY INTERNATIONAL

C3 glomerulopathy associated with monoclonal Ig is a distinct subtype

(2018) Aishwarya Ravindran et al.   KIDNEY INTERNATIONAL

A clone-directed approach may improve diagnosis and treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits

(2018) Ramnika Gumber et al.   KIDNEY INTERNATIONAL

Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma

(2016) J. Krejcik et al.   BLOOD

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

(2016) Pamela L. Clemens et al.   CLINICAL PHARMACOKINETICS

Spectrum of manifestations of monoclonal gammopathy-associated renal lesions

(2016) Sanjeev Sethi et al.   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hematologic Characteristics of Proliferative Glomerulonephritides With Nonorganized Monoclonal Immunoglobulin Deposits

(2015) Gauri Bhutani et al.   MAYO CLINIC PROCEEDINGS

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series

(2013) Ladan Zand et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant

(2012) N. Leung et al.   BLOOD

Glomerulonephritis With Isolated C3 Deposits and Monoclonal Gammopathy: A Fortuitous Association?

(2011) F. Bridoux et al.   Clinical Journal of the American Society of Nephrology

Patterns of Noncryoglobulinemic Glomerulonephritis with Monoclonal Ig Deposits: Correlation with IgG Subclass and Response to Rituximab

(2011) E. Guiard et al.   Clinical Journal of the American Society of Nephrology

Dense Deposit Disease Associated With Monoclonal Gammopathy of Undetermined Significance

(2010) Sanjeev Sethi et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Membranoproliferative Glomerulonephritis Secondary to Monoclonal Gammopathy

(2010) S. Sethi et al.   Clinical Journal of the American Society of Nephrology

Proliferative Glomerulonephritis with Monoclonal IgG Deposits

(2009) S. H. Nasr et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY